- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Interventions
- Magnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration
- Procedure · Other · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Richmond, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–43
of 19
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer, Overweight or Obesity
- Interventions
- Contrave, Behavioral Weight Loss
- Drug · Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
- Interventions
- Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases, Parkinsonian Disorders, Genetic Predisposition
- Interventions
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Behavioral
- Lead sponsor
- Radboud University Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- 18F-FGLN PET Imaging, (18F)FPGLU
- Diagnostic Test · Drug
- Lead sponsor
- Stephen Y. Chan
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 26
- States / cities
- Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more
- Conditions
- Breast Cancer
- Interventions
- 18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
- Drug · Device · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Placebo, LY3202626
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more
- Conditions
- AMCI - Amnestic Mild Cognitive Impairment, Sleep Disturbance
- Interventions
- Trazodone, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Preterm Infant
- Interventions
- Early/Slow, Early/Fast, Late/Slow, Late/Fast
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 32 Weeks
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Sleep Deprivation, Sleep
- Interventions
- Sleep deprivation, Nap
- Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- VB11, Surgery, Placebo, Bevacizumab
- Drug · Procedure · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
- Interventions
- Venetoclax, Lenalidomide, Rituximab, Rituximab and Hyaluronidase Human
- Drug · Biological
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PTSD
- Interventions
- Prolonged Exposure for Primary Care (PE-PC), Full Prolonged Exposure, Clinician Supported PTSD Coach App
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Baldwin, Michigan • Battle Creek, Michigan • Flint, Michigan + 9 more
- Conditions
- Delirium, Delirium in Old Age, Critical Illness, Intensive Care Unit Delirium
- Interventions
- EyeControl-Pro, Control
- Device · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Cirrhosis, Liver Transplant Disorder
- Interventions
- Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Deafness
- Interventions
- Single-Electrode Pulse Train, Modulation Detection Threshold (MDT) and Gap Detection Tasks, Sound coding strategy., Electric-only spectral resolution
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 6 Years to 80 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hodgkin Lymphoma
- Interventions
- pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, etoposide, Radiotherapy (RT)
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- JASPER, JASPER Plus+
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 24 Months to 36 Months
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York